EMERGENT BIOSOLUTIONS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
EMERGENT BIOSOLUTIONS INC. (EBS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.35 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.35, a 70.03% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $17.85, a 49.23% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $35.16, a 62.10% increase from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $21.69, a 2.65% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2023-12-31 | $5.35 10-K · filed 2024-03-08 |
| 2022-12-31 | $17.85 10-K · filed 2024-03-08 |
| 2021-12-31 | $35.16 10-K · filed 2024-03-08 |
| 2020-12-31 | $21.69 10-K/A · filed 2023-12-11 |
| 2019-12-31 | $21.13 10-K · filed 2022-02-25 |
| 2018-12-31 | $18.48 10-K · filed 2021-02-19 |
| 2017-12-31 | $10.53 10-K · filed 2020-02-25 |
| 2012-12-31 | $5.16 10-K · filed 2013-03-08 |
| 2011-12-31 | $10.09 10-K · filed 2013-03-08 |
| 2010-12-31 | $6.48 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |